Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Dec;30(12):2660-2663.
doi: 10.3201/eid3012.241089.

Lobomycosis in Amazon Region, Bolivia, 2022

Case Reports

Lobomycosis in Amazon Region, Bolivia, 2022

Maria I Méndez et al. Emerg Infect Dis. 2024 Dec.

Abstract

We report a patient with lobomycosis caused by Paracoccidioides loboi fungi in the Andes-Amazon region of Bolivia. We examined clinical, epidemiologic, and phylogenetic data and describe potential transmission/environmental aspects of infection. Continued surveillance and identification of lobomycosis cases in South America are crucial to prevent the spread of this disease.

Keywords: Amazon; Andes; Bolivia; Lacazia loboi; Paraccocidiodes loboi; fungi; lobomycosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical manifestations of lesions in patient with lobomycosis in Amazon Region, Bolivia, 2022. A) Multiple hyperpigmented, confluent keloid-like nodular lesions with overriding telangiectasias and patchy crusted and eroded squamous areas were noted on the helix and lobule of the left ear. B, C) Histologic examination of lesion specimens showed oval-to-round shaped cells that had connecting tubular projections organized in a string-of-pearls pattern, in pairs and individually. B) Fontana-Masson stain; original magnification ×1,000. C) Gömöri methenamine silver stain; original magnification ×400.
Figure 2
Figure 2
Phylogenetic analysis of genes from different Paracoccidioides spp. in study of lobomycosis in Amazon Region, Bolivia, 2022. Phylogenetic trees were inferred by using the maximum-likelihood method for ADP-rf (A), GP43 (B), and ITS1/ITS2 (C) genes. Sequences obtained from GenBank were compared with sequences from the patient sample (sequences deposited in European Nucleotide Archive [https://www.ebi.ac.uk/ena] under Bioproject no. PRJEB77911). Scale bars indicate nucleotide substitutions per site.

References

    1. Paniz-Mondolfi A, Talhari C, Sander Hoffmann L, Connor DL, Talhari S, Bermudez-Villapol L, et al. Lobomycosis: an emerging disease in humans and delphinidae. Mycoses. 2012;55:298–309. 10.1111/j.1439-0507.2012.02184.x - DOI - PubMed
    1. Recacoechea M, Vargas J. Experiencia con el ketoconazole en el primer caso de lobomicosis en Bolivia. Bol. inf CENETROP. 1982;8:23–6.
    1. Brito AC, Quaresma JAS. Lacaziose (doença de Jorge Lobo): revisão e atualização. An Bras Dermatol. 2007;82:461–74. 10.1590/S0365-05962007000500010 - DOI
    1. Vilela R, Huebner M, Vilela C, Vilela G, Pettersen B, Oliveira C, et al. The taxonomy of two uncultivated fungal mammalian pathogens is revealed through phylogeny and population genetic analyses. Sci Rep. 2021;11:18119. 10.1038/s41598-021-97429-7 - DOI - PMC - PubMed
    1. Gonçalves FG, Rosa PS, Belone AFF, Carneiro LB, de Barros VLQ, Bispo RF, et al. Lobomycosis epidemiology and management: the quest for a cure for the most neglected of neglected tropical diseases. J Fungi (Basel). 2022;8:494. 10.3390/jof8050494 - DOI - PMC - PubMed

Publication types

LinkOut - more resources